Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

ClinicalTrials.gov ID: NCT00656734

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00656734. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label, Multicenter Dose-escalation, Multidose Study of MDX1411 Administered Every 14 Days in Subjects With Advanced or Recurrent Clear Cell Renal Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To determine the highest and safest tolerated dose of MDX-1411 for the treatment of clear cell renal cell carcinoma (Kidney cancer).

Study identification

NCT ID: NCT00656734
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 27 participants

Conditions and interventions

Conditions

Kidney Cancer

Interventions

MDX 1411 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2008 (Type not available)
Primary completion: Jun 2010 (Actual)
Completion: Jun 2010 (Actual)
Last update posted: May 14, 2013

2008 – 2010

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
Beth Israel Deaconness Medical Center	Boston	Massachusetts	02215	—
Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	48201	—
Nevada Cancer Institute	Las Vegas	Nevada	89135	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Montefiore Medical Center	The Bronx	New York	10466	—
Cleveland Clinic Taussig Cancer Center	Cleveland	Ohio	44195	—
Providence Portland Medical Center	Portland	Oregon	97213	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00656734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 14, 2013 · Synced Nov 15, 2026